NASDAQ Global Select • Healthcare • Biotechnology • US • USD
Spero Therapeutics, Inc. (SPRO) has a consensus analyst rating of Buy, based on 13 analysts covering the stock. Of those, 6 recommend buying, 5 recommend holding, and 2 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
